RBR-75jm4cj招募中2 期

Open-label, pilot, randomized clinical trial evaluating the effect of withdrawing renin-angiotensin-system inhibitors and neprilisin inhibitors and maintaining Carvedilol in Heart Failure with recovered ejection fraction

适应症

试验速览

阶段: 2 期
状态: 招募中
发起方: Instituto do Coração do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo

暂无简介。

•Patients with previous diagnosis of reduced ejection fraction heart failure and documented ejection fraction equal or under 40% and actual ejection fraction equal or more than 50% and 10% greater than previous; Age equal or greater than 18 years old; absence of symptoms related to heart failure; Currently using carvedilol and angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers or neprilisin inhibitor with or without spironolactone; NT-proBNP under 250pg/mL; heart rate between 50 and 60 or maximum tolerated dose of carvedilol after runin fase or at least 50mg/day of carvedilol.

•Ischemic cardiomyopathy; hypertensive cardiomyopathy: stage 3 hypertension as defined by the Brazilian Guideline of Hypertension or current blood pressure higher than 160x90mmHg; chagasic cardiomyopathy; valvar cardiomyopathy; infiltrative cardiomyopathy; chronic renal disease with creatinine clearance less than 30mL/min/1,73m²; formal indication for angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers such as diabetic patients with hypertension, diabetic nephropathy or another nephropathy with proteinuria.

发起方